Neurocrine expects double-digit 2027 INGREZZA volume growth despite mid- to high single-digit net pricing headwinds
Neurocrine projected double-digit volume growth for INGREZZA in 2027 while anticipating mid- to high-single-digit net pricing headwinds.
The current stock price is positioned midway between the 20-day resistance line ($149.25) and support line ($132.25), with trading volume slightly exceeding the 20-day average to maintain moderate momentum. Therefore, entry will be considered based on this price level and volume trend.
I will take profit if the stock price reaches the 20-day resistance level of $149.25, and cut losses if the 20-day support level of $132.25 is breached.
RSI (14) shows a mild upward momentum at 60.0, the moving averages are in a non-bullish alignment, trading volume is at 1.07 times the 20-day average, and the volatility over the past 7 days recorded +3.4%.
Although a conservative approach was taken with a projected return of 2.1%, the actual result recorded a return of 13.4%, resulting in an OVERHIT rating. At the time of entry, the stock price was positioned midway between the 20-day resistance line ($149.25) and support line ($132.25), and trading volume was 1.07 times the 20-day average, maintaining mild momentum, which led to expectations of a limited upside. However, the Q3 earnings beat and guidance upgrade news released just before entry provided explosive momentum to the stock price (candle on 2026-11-03: open 159.0, high 169.53, close 164.85), recording a surge that far exceeded the expected resistance line of $149.25. Interpreting the strength of the positive news and the market's reaction speed too conservatively created the divergence from the actual return.
During periods accompanied by strong catalysts such as earnings announcements and guidance upward revisions, we should avoid being confined solely to mechanical resistance-level price targets and instead establish a flexible take-profit strategy that leaves room for momentum expansion. Going forward, when similar favorable disclosures coincide with increased trading volume, we will implement a phased take-profit approach to capture a longer upward trend.